CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 1,212 enrolled
Drug / intervention
adalimumabdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00237887
NCT00237887Phase 3Completed
CompareCT.gov

A Phase III, Multicenter Study of the Efficacy and Safety of Adalimumab Treatment in Subjects With Moderate to Severe Chronic Plaque Psoriasis

Abbott·interventional·Posted Oct 13, 2005·Updated Aug 29, 2007

In Brief

A Phase 3 clinical trial evaluating adalimumab for Psoriasis. Completed, enrolled 1,212 participants.

Detailed Summary

A Phase III, Multicenter Study of the Efficacy and Safety of Adalimumab Treatment in Subjects with Moderate to Severe Chronic Plaque Psoriasis

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPsoriasis
Countries--
Collaborators--

Timeline

Phase 3CompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedOct 13, 2005
Enrollment StartDec 1, 2004
TodayJul 2, 2026
Posted 20.7 years ago

Interventions

adalimumabdrug